Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.42 |
| ▸ | ANPEP | P15144 | 3/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.41 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27798628 | 0.83 | ATM (0.38) | ALDH1A1LMNATP53SMN1; SMN2 | |
| SCHEMBL8850414 | 0.82 | CYP1A2 (0.39) | SLC7A5LTA4HALDH1A1 | |
| SCHEMBL5016829 | 0.81 | ALPI (0.51) | ANPEPRNPEPDNPEPSLC7A5LTA4H | |
| SCHEMBL9100092 | 0.81 | ALPI (0.51) | ANPEPRNPEPDNPEPSLC7A5LTA4H | |
| SCHEMBL27342871 | 0.80 | CYP1A2 (0.40) | ANPEPLTA4HALDH1A1 | |
| SCHEMBL11212470 | 0.79 | LARS1 (0.48) | LARS1ANPEPRNPEPDNPEPSLC7A5 | |
| SCHEMBL9391207 | 0.78 | DPP7 (0.43) | LTA4H | |
| SCHEMBL6581938 | 0.74 | LARS1 (0.47) | LARS1ANPEPRNPEPDNPEPSLC7A5 | |
| SCHEMBL8074243 | 0.74 | GPR88 (0.44) | LARS1ANPEPRNPEPDNPEPGPR88 | |
| SCHEMBL8074241 | 0.74 | GPR88 (0.44) | LARS1ANPEPRNPEPDNPEPGPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9182401-B2 | Use of the IRAP protein for implementing methods of diagnosis and of prognosis | UNIVERSITE JOSEPH FOURIER (FR) | 2015-11-10 | — | — | US | disclosed |
| EP-2297205-B1 | USE OF THE IRAP PROTEIN FOR IMPLEMENTING METHODS OF DIAGNOSIS AND OF PROGNOSIS | UNIV JOSEPH FOURIER (FR) | 2013-12-25 | — | — | EP | disclosed |
| US-20120115163-A1 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2012-05-10 | — | — | US | disclosed |
| EP-2432800-A2 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | Université Joseph Fourier (FR) | 2012-03-28 | — | — | EP | disclosed |
| US-20110201021-A1 | USE OF THE IRAP PROTEIN FOR IMPLEMENTING METHODS OF DIAGNOSIS AND OF PROGNOSIS | UNIVERSITE JOSEPH FOURIER (FR) | 2011-08-18 | — | — | US | disclosed |
| EP-2297205-A1 | USE OF THE IRAP PROTEIN FOR IMPLEMENTING METHODS OF DIAGNOSIS AND OF PROGNOSIS | Université Joseph Fourier (FR) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010133806-A2 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | UNIVERSITE JOSEPH FOURIER (FR) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010001079-A1 | USE OF THE IRAP PROTEIN FOR IMPLEMENTING METHODS OF DIAGNOSIS AND OF PROGNOSIS | UNIVERSITE JOSEPH FOURIER (FR) | 2010-01-07 | — | — | WO | disclosed |
| US-20080171370-A1 | DETOXIFYING PRE-TREATED LIGNOCELLULOSE-CONTAINING MATERIALS | NOVOZYMES NORTH AMERICA, INC. (US) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115163-A1 | MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP | IAPP, ANPEP, ENPEP | LARS1 1283/4885ANPEP 2/4885RNPEP 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.